ContextLogic Inc (LOGC)
| Market Cap | 138.87M |
| Revenue (ttm) | 227.00M |
| Net Income (ttm) | -287.00M |
| Shares Out | 24.49M |
| EPS (ttm) | -11.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,031 |
| Open | 5.55 |
| Previous Close | 5.53 |
| Day's Range | 5.48 - 5.67 |
| 52-Week Range | 3.55 - 9.90 |
| Beta | 2.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 1, 2024 |
About LOGC
ContextLogic Inc. operates as a mobile ecommerce company in Europe, North America, South America, and internationally. The company operates Wish, an ecommerce platform that connects consumers to merchants. It also provides marketplace and logistics services to merchants. ContextLogic Inc. was incorporated in 2010 and is headquartered in San Francisco, California. [Read more]
News
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine ...
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality w...
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat...
SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LogicBio Therapeutics, Inc. ("LogicBio" ...
Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca
MILWAUKEE , Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. Cl...
LogicBio's stock skyrockets after buyout bid for a 667% premium
Shares of LogicBio Therapeutics Inc. LOGC, +641.32% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company a...
LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per shar...
AstraZeneca pays 660% premium for gene therapy firm LogicBio
Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ:...
LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE
Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet. LEXINGTON, Mass.
LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression - Two of four patients demon...
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Freder...
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
–FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 –LogicB...
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
- GeneRide ® LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers -Proprietary AAV transfection process, harnessing mAAVRx™ system, showed 15- to...
Why LogicBio Therapeutics Shares Are Popping Off Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, a...
LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial
The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatri...
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
–Company initiates activities to resume dosing –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LEXINGTON, Mass. , May 9, 2022 /PRNewswire/ -- LogicBi...
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, ...
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
LEXINGTON, Mass., March 8, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred...
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31,...
Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today?
The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after two a...
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program
LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development progra...
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Ch...
LogicBio Therapeutics Provides Business Updates
LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical tria...